Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are hypothesized to exert a positive effect on inflammatory markers in T2DM patients with few data from small pilot studies, which confirms a reduction in leptin levels, C-reactive protein (CRP), TNF-α, IL-6, and interferon-gamma (IFN-γ) [94,95]. Here, CRP is linked to type 2 diabetes mellitus.